PEG

Essential Utilities Announces Election of Christopher Bruner and Tamara Linde to Board of Directors

Retrieved on: 
星期四, 五月 2, 2024
Energy, Utilities, Oil, Gas, Education, EEI, American Arbitration Association, Law, Executive, Community foundation, Essential Utilities, Risk, EY, General counsel, Policy, Public Service Enterprise Group, Union League, Linde, National Association, AAA, JD, Audit committee, Multimedia, Edison Electric Institute, WTRG, Seton Hall University, Ernst & Young, PEG, Union, Audit

Essential Utilities Inc. (NYSE: WTRG) announces Christopher Bruner and Tamara Linde as the newest members of its board of directors.

Key Points: 
  • Essential Utilities Inc. (NYSE: WTRG) announces Christopher Bruner and Tamara Linde as the newest members of its board of directors.
  • Mr. Bruner will chair Essential’s audit committee and serve on the executive compensation committee.
  • Ms. Linde will serve on the corporate governance committee and the risk mitigation and investment policy committee.
  • View the full release here: https://www.businesswire.com/news/home/20240502139650/en/
    Essential Utilities Announces Election of Christopher Bruner to Board of Directors.

Hurricane Preparedness Week: PSEG Long Island Announces Climate Change Resilience Plan

Retrieved on: 
星期五, 五月 3, 2024
LIPA, Climate change, Weather, State, CCRP, Climate, Partnership, Columbia University, Assume Form, Long Island Power Authority, Atlantic Ocean, Federal Emergency Management Agency, Rest, Emergency, Wind, Public Service Commission, Tablet, CAC, National Hurricane Preparedness Week, Public service law, NYPA, PEG, CCVS, Mobile phone

UNIONDALE, N.Y., May 3, 2024 /PRNewswire/ -- PSEG Long Island has spent the last decade preparing the utility and the electric grid for hurricanes and other extreme weather. On National Hurricane Preparedness Week, May 5-11, the company announced it is also developing a proactive Climate Change Resilience Plan in partnership with the Long Island Power Authority (LIPA) to address changes in weather patterns projected to occur over the coming decades.

Key Points: 
  • On National Hurricane Preparedness Week, May 5-11, the company announced it is also developing a proactive Climate Change Resilience Plan in partnership with the Long Island Power Authority (LIPA) to address changes in weather patterns projected to occur over the coming decades.
  • PSEG Long Island is also pleased to announce that the findings of its recent Climate Change Vulnerability Study are shaping an in-depth Climate Change Resilience Plan to be published by PSEG Long Island and LIPA later this year.
  • PSEG Long Island operates the Long Island Power Authority's transmission and distribution system under a long-term contract.
  • PSEG Long Island is a subsidiary of Public Service Enterprise Group Inc. (PSEG) (NYSE:PEG), a publicly traded diversified energy company.

ProLynx announces initiation of the Phase II Topology clinical trial of its DNA-damaging agent PLX038 in triple-negative breast cancer at the Institut Curie

Retrieved on: 
星期一, 三月 25, 2024
Cloud, RB1, Hydrolysis, Irinotecan, Progression-free survival, Patient, SAN, Biomarker, Research, DNA, Cancer, Cmax, SN-38, Clinical trial, Curie Institute (Paris), Safety, Prodrug, Homologous recombination, ADC, TNBC, Teaching, PEG

Patients will have been previously treated with at least two therapies, including the antibody-drug conjugate (ADC) sacituzumab govitecan (SG; Trodelvy).

Key Points: 
  • Patients will have been previously treated with at least two therapies, including the antibody-drug conjugate (ADC) sacituzumab govitecan (SG; Trodelvy).
  • The TOPOLOGY trial is run by Institut Curie (Paris and Saint Cloud, France), with principal investigator Prof. Francois-Clement Bidard .
  • PLX038 is a long-acting prodrug of the topoisomerase 1 (Top1) inhibitor, SN-38, which is also the active component of anti-cancer agents irinotecan and the ADC SC.
  • Institut Curie has 3 sites (Paris, Saint-Cloud and Orsay) with over 3,700 health professionals working on treatment, research and teaching ([email protected]) Information on this clinical trial is available at clinicaltrials.gov, NCT06162351.

Global Enteral Feeding Devices Market Insights 2024-2029 with Avanos Medical and B. Braun Melsungen Leading through Substantial R&D Investments - ResearchAndMarkets.com

Retrieved on: 
星期二, 三月 12, 2024
Health, Medical Devices, Other Health, Hospital, Cardiology, Incidence, Enterostomy, Neurology, Conditional sentence, Growth, Prevalence, Obesity, Esophagitis, DSM-IV codes, Patient, Research, GI, Cancer, HEN, Crohn's disease, Ageing, Parenteral nutrition, Syringe, Diet, Gastrointestinal disease, Investment, Malnutrition, Safety, IBS, Dysphagia, USD, Avanos Medical, Tubing (recreation), Pediatrics, PEG

The enteral feeding devices market features diverse players, from well-established giants to dynamic emerging entities, focusing on innovation and strategic growth.

Key Points: 
  • The enteral feeding devices market features diverse players, from well-established giants to dynamic emerging entities, focusing on innovation and strategic growth.
  • Leading firms such as Avanos Medical and B. Braun Melsungen distinguish themselves through substantial research and development (R&D) investments, forming strategic alliances, and initiatives to increase their market share.
  • The enteral feeding devices market is set for sustained growth, driven by healthcare advancements and a global emphasis on chronic disease management and nutritional support.
  • North America, particularly the United States and Canada, leads in the enteral feeding devices market.

PSE&G's Energy Efficiency Programs Projected to Save $445M and Avoid Approximately 1.5M Metric Tons of Carbon Emissions Annually

Retrieved on: 
星期四, 四月 4, 2024
Electricity, CEF, Dow Jones, Natural gas, EnergySolutions, Gas, J.D. Power, Edison Electric Institute, C&I, Mid-Atlantic (United States), Carbon, Partner, PEG, Renewable energy

NEWARK, N.J., April 4, 2024 /PRNewswire/ -- PSE&G's latest report on its Clean Energy Future Energy Efficiency (CEF-EE) initiatives indicates a continuation of significant accomplishments from programs through December 31, 2023. Since the start of the CEF-EE program, approximately 1.8 million customers have benefited from PSE&G's energy-saving tools, receiving valuable insights through energy usage reports, with about 360,000 taking action to save energy and money through PSE&G's suite of energy efficiency programs.

Key Points: 
  • Participating customers are projected to save a collective $445 million[i] annually on their utility bills thanks to various program initiatives such as conducting approximately 65,000 home energy assessments[ii].
  • Additionally, participating natural gas customers are expected to save approximately 52 million therms of natural gas annually.
  • Together, these efforts are estimated to avoid about 1.5 million metric tons of carbon dioxide emissions annually[iv], roughly equivalent to the emissions from 325,000 gasoline-powered cars on the road for a year[v].
  • For more information on PSE&G's energy efficiency programs, including how to participate, visit homeenergy.pseg.com for residential customers or bizsave.pseg.com for business customers.

PEG, LLC Earns 2024 Energy Star® Sustained Excellence Award

Retrieved on: 
星期四, 三月 28, 2024
Electricity, Professional, Climate change, Organization, Environment, Public, Sale, Private sector, EPA, PEG, Renewable energy

FAIRFAX, Va., March 27, 2024 /PRNewswire-PRWeb/ -- PEG, LLC is proud to announce that it has received the 2024 ENERGY STAR Partner of the Year – Sustained Excellence Award from the U.S. Environmental Protection Agency.

Key Points: 
  • FAIRFAX, Va., March 27, 2024 /PRNewswire-PRWeb/ -- PEG, LLC is proud to announce that it has received the 2024 ENERGY STAR Partner of the Year – Sustained Excellence Award from the U.S. Environmental Protection Agency.
  • The Sustained Excellence award is the highest honor bestowed by the ENERGY STAR program.
  • Each year, the ENERGY STAR program honors a select group of businesses and organizations that have made outstanding contributions to energy efficiency and the transition to a clean energy economy.
  • ENERGY STAR award winners lead their industries in the production, sale, and adoption of energy-efficient products, homes, buildings, services, and strategies.

PSEG Long Island Urges Customers to Know What to Do if Visited by Someone Dressed as a Utility Worker

Retrieved on: 
星期五, 二月 9, 2024
Bitcoin, Collection, Address, URL, Long Island Power Authority, PIN, ID, Safety, PEG, Water, Public Service Enterprise Group, Online shopping

UNIONDALE, N.Y., Feb. 9, 2024 /PRNewswire/ -- In light of a recent home invasion incident in Nassau County involving robbers dressed as utility workers, PSEG Long Island urges customers to know what its employees look like and what they typically do when making visits to a home.

Key Points: 
  • "The safety of customers and employees is our top priority at PSEG Long Island," said Lou Debrino, vice president of Customer Operations for PSEG Long Island.
  • PSEG Long Island reminds customers do the right thing if confronted with a demand for payment and a threat of imminent shutoff: Get the truth from real PSEG Long Island representatives at 1-800-490-0025.
  • PSEG Long Island operates the Long Island Power Authority's transmission and distribution system under a long-term contract.
  • PSEG Long Island is a subsidiary of Public Service Enterprise Group Inc. (PSEG) (NYSE:PEG), a publicly traded diversified energy company.

Delta-Fly Pharma Inc.: Abstracts submission for Phase I Clinical Trial of DFP-14927 to 2024 ASCO annual meeting

Retrieved on: 
星期三, 二月 7, 2024
Oncology, Health, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, Neoplasm, Acute myeloid leukemia, Permeability, Patient, ASCO, MD Anderson Cancer Center, AML, Myelodysplastic syndrome, Marketing, PEG, MDS, DDS, Blood, Spacecraft, Colorectal cancer, University, Cancer, Atomic mass

in 2024, we are excited to share our latest development status.

Key Points: 
  • in 2024, we are excited to share our latest development status.
  • A Phase I clinical dose-finding study of DFP-14927 in patients with solid tumors has been completed at MD Anderson Cancer Center and the University of California, Los Angeles in the United States.
  • Subsequently, the concentration of DFP-10917, the active component of DFP-14927, delivering into cancer tissue in patients treated with DFP-14927 is being measured to confirm PK/PD relationship for the clinical efficacy of DFP-14927.
  • On 6th Feb. 2024, we are pleased to announce that we have submitted an abstract to the 2024 ASCO annual meeting to be held from May 31st this year in Chicago.

ZWI Therapeutics, Inc. Announces a Series A Financing, Two Accomplished Biopharmaceutical CEOs Join the Board of Directors, and Appointment of Chief Executive Officer

Retrieved on: 
星期三, 一月 24, 2024
Hyperuricemia, CMC, Therapy, DRS, PEG, Alex Mascioli, IND, Family, Cornell University, Polymer, FDA, Gout, Friends, Pharmacokinetics, Publication, Gel, Pharmaceutical industry

Larry Miller and Ron Cohen as Independent Directors to the company's Board of Directors, and Dr. Ed Mascioli as Chief Executive Officer and Board Director.

Key Points: 
  • Larry Miller and Ron Cohen as Independent Directors to the company's Board of Directors, and Dr. Ed Mascioli as Chief Executive Officer and Board Director.
  • Ed Mascioli's significant experience leading multiple biotech companies is important in our Company's growth" said Dr. Shaoyi Jiang, the Robert Langer '70 Family and Friends Professor at Cornell University, ZWI Board member, and co-founder.
  • "As board members, Ron and Larry collectively bring decades of successful pharmaceutical industry experience to ZWI.
  • ZWI has gained meaningful guidance on CMC, non-clinical, and clinical plans from the FDA via an INTERACT meeting and is progressing toward filing an IND.

Delta-Fly Pharma Inc.: Update on the R&D status of DFP-10917 and DFP-14927, a novel PEG Drug Conjugate, in the patients with R/R AML

Retrieved on: 
星期五, 一月 5, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Neoplasm, PEGylation, PEG, Cancer, Patent, VTX, Patient, Acute myeloid leukemia, ADC, AML, Pharmaceutical industry

Following the previous information on June 30th in 2023, we are excited to share our latest development status.

Key Points: 
  • Following the previous information on June 30th in 2023, we are excited to share our latest development status.
  • A Phase III study of DFP-10917 in patients with recurrent or refractory acute myeloid leukemia (R/R AML) at multicenter in the US is undergoing of the interim analysis.
  • A Phase I/II study of DFP-10917 in the combination with Venetoclax (VTX) in patients with R/R AML in the U.S. is in preparation.
  • Please find out the innovation for the miserable cancer patients by Delta-Fly Pharma Inc. and contact with us.